O21 Is SLE-DAS better than BILAG-2004 to identify severe SLE disease activity? Post-hoc analysis of 438 SLE patients from the anifrolumab clinical trials

• Andrea Doria,
• Diogo Jesus,
• Ana Matos,
• Carla Henriques,
• Luís Sousa Inês

Affiliations

Andrea Doria

1Department of Medicine, University of Padua, Italy

Diogo Jesus

Rheumatology Department, Centro Hospitalar de Leiria, Leiria, Portugal

Ana Matos

5Research Centre in Digital Services (CISeD), Viseu, Portugal

Carla Henriques

School of Technology and Management, Polytechnic Institute of Viseu, Viseu, Portugal

Luís Sousa Inês

7CHUC Lupus Clinic, Rheumatology Dept., Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal